Addendum
Mepolizumab (hypereosinophilic syndrome) – Addendum to Commission A21-152
Report documents
-
Addendum
Mepolizumab (hypereosinophilic syndrome) – Addendum to Commission A21-152
Dossier assessment
Indication:
Add-on therapy for adult patients with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematological secondary cause
Result of dossier assessment:
After addendum: Hint of major added benefit
Additional information
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.
Project details
- Project no.
- A22-45
- Commission
- Commission awarded on 12.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed